|
|
Blood, 1 June 2005, Vol. 105, No. 11, pp. 4191-4199.
Prepublished online as a Blood First Edition Paper on February 8, 2005; DOI 10.1182/blood-2004-12-4726.
Previous Article | Next Article 
Submitted December 13, 2004
Accepted January 28, 2005
Leukocyte migration and graft-versus-host disease
Christian A Wysocki, Angela Panoskaltsis-Mortari, Bruce R Blazar, and Jonathan S Serody*
Departments of Medicine, Microbiology and Immunology, and the Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Department of Pediatrics, Division of Pediatric Bone Marrow Transplantation, and the University of Minnesota Cancer Center, University of Minnesota, Minneapolis, MN, USA
* Corresponding author; email: onathan_Serody{at}med.unc.edu.
Graft-versus-host disease (GVHD) remains a significant complication of allogeneic bone marrow transplantation (allo-BMT). Acute GVHD is mediated by immunocompetent donor T cells, which migrate to lymphoid tissues soon after infusion, recognize host alloantigens, and become activated upon interaction with host antigen presenting cells (APCs). Recent work from our group and others suggests that activated effector T cells exit lymphoid tissues and traffic to mucosal sites and parenchymal target organs such as the GI tract, liver, lung, and skin where they cause tissue damage. The molecular interactions necessary for effector cell migration during GVHD have become the focus of a growing body of research, as these interactions represent potential therapeutic targets. In this review we will discuss chemokine/chemokine receptor interactions and adhesion molecules that have been shown to play roles in effector cell migration in experimental GVHD models, and discuss a potential model for the role of chemokines during the activation phase of GVHD.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
T. Yi, D. Zhao, C.-L. Lin, C. Zhang, Y. Chen, I. Todorov, T. LeBon, F. Kandeel, S. Forman, and D. Zeng
Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease
Blood,
September 1, 2008;
112(5):
2101 - 2110.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Hori, Y. Naishiro, H. Sohma, N. Suzuki, N. Hatakeyama, M. Yamamoto, T. Sonoda, Y. Mizue, K. Imai, H. Tsutsumi, et al.
CCL8 is a potential molecular candidate for the diagnosis of graft-versus-host disease
Blood,
April 15, 2008;
111(8):
4403 - 4412.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. D. Kim, T. H. Terwey, J. L. Zakrzewski, D. Suh, A. A. Kochman, M. E. Chen, C. G. King, C. Borsotti, J. Grubin, O. M. Smith, et al.
Organ-derived dendritic cells have differential effects on alloreactive T cells
Blood,
March 1, 2008;
111(5):
2929 - 2940.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Zheng, C. Matte-Martone, H. Li, B. E. Anderson, S. Venketesan, H. Sheng Tan, D. Jain, J. McNiff, and W. D. Shlomchik
Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease
Blood,
February 15, 2008;
111(4):
2476 - 2484.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Liang, C. Liu, J. Y. Djeu, B. Zhong, T. Peters, K. Scharffetter-Kochanek, C. Anasetti, and X.-Z. Yu
2 integrins separate graft-versus-host disease and graft-versus-leukemia effects
Blood,
January 15, 2008;
111(2):
954 - 962.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. P. Piper, C. Horlock, S. J. Curnow, J. Arrazi, S. Nicholls, P. Mahendra, C. Craddock, and P. A. H. Moss
CXCL10-CXCR3 interactions play an important role in the pathogenesis of acute graft-versus-host disease in the skin following allogeneic stem-cell transplantation
Blood,
December 1, 2007;
110(12):
3827 - 3832.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Durakovic, V. Radojcic, M. Skarica, K. B. Bezak, J. D. Powell, E. J. Fuchs, and L. Luznik
Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse
Blood,
May 15, 2007;
109(10):
4564 - 4574.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Zhang, J. Lou, N. Li, I. Todorov, C.-L. Lin, Y.-A. Cao, C. H. Contag, F. Kandeel, S. Forman, and D. Zeng
Donor CD8+ T Cells Mediate Graft-versus-Leukemia Activity without Clinical Signs of Graft-versus-Host Disease in Recipients Conditioned with Anti-CD3 Monoclonal Antibody
J. Immunol.,
January 15, 2007;
178(2):
838 - 850.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Ueha, M. Murai, H. Yoneyama, M. Kitabatake, T. Imai, T. Shimaoka, S. Yonehara, S. Ishikawa, and K. Matsushima
Intervention of MAdCAM-1 or fractalkine alleviates graft-versus-host reaction associated intestinal injury while preserving graft-versus-tumor effects
J. Leukoc. Biol.,
January 1, 2007;
81(1):
176 - 185.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. N. Ajuebor, J. A. Carey, and M. G. Swain
CCR5 in T Cell-Mediated Liver Diseases: What's Going On?
J. Immunol.,
August 15, 2006;
177(4):
2039 - 2045.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Chakraverty, D. Cote, J. Buchli, P. Cotter, R. Hsu, G. Zhao, T. Sachs, C. M. Pitsillides, R. Bronson, T. Means, et al.
An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues
J. Exp. Med.,
August 7, 2006;
203(8):
2021 - 2031.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Waldman, S. X. Lu, V. M. Hubbard, A. A. Kochman, J. M. Eng, T. H. Terwey, S. J. Muriglan, T. D. Kim, G. Heller, G. F. Murphy, et al.
Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine
Blood,
February 15, 2006;
107(4):
1703 - 1711.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. H. Terwey, T. D. Kim, A. A. Kochman, V. M. Hubbard, S. Lu, J. L. Zakrzewski, T. Ramirez-Montagut, J. M. Eng, S. J. Muriglan, G. Heller, et al.
CCR2 is required for CD8-induced graft-versus-host disease
Blood,
November 1, 2005;
106(9):
3322 - 3330.
[Abstract]
[Full Text]
[PDF]
|
 |
|
| |